Nintedanib in NSCLC: evidence to date and place in therapy
| Autor: | Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, Nadia Barraco, Angela Listì, Marta Castiglia, Sergio Rizzo, Eugenio Fiorentino, Viviana Bazan, Antonio Russo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Medical Oncology, Vol 8 (2016) |
| Druh dokumentu: | article |
| ISSN: | 1758-8359 17588340 |
| DOI: | 10.1177/1758834016630976 |
| Popis: | The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|